Drug Discovery News: Breaking Drug Discovery News, Comments and Articles. - Page: 4

21:27 EDT 20th April 2015 | BioPortfolio

Drug Discovery News - Page: 4Twitter RSS

Read the latest Drug Discovery News from around the world, updated every five minutes. Breaking stories from leading news and press agencies, bloggers and experts on Drug Discovery.

Search or Follow Our Drug Discovery - Page: 4 News…

If you are looking for more stories, you may wish to search our extensive news archives for relevant stories: Search for More Drug Discovery - Page: 4 News.
You can also follow our Drug Discovery - Page: 4 news stories on Twitter: @DiscoveryDrug

Showing "drug drug discovery discovery" News Articles 76 to 100 of 25,000+

Monday 20th April 2015

New drug combination shows promise for breaking breast cancer resistance

Researchers from The University of Manchester working with drug development company Evgen Pharma, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.

Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer

First of several registration trials expected to start in 2015 for the alliance between Merck KGaA, Darmstadt, Germany, and Pfizer Initiation and first patient treated in Phase III clinical study recruiting across approximately 290 sites in more than 30 countries The primary endpoint of the study is overall survival (OS)...

Bio Products Laboratory, Ltd. Announces Results from Phase III Registration Study of its Factor X Coagulation Product

Bio Products Laboratory, Ltd. (BPL), a leading manufacturer of plasma-derived protein therapies, today announced the results from a phase III registration study examining the pharmacokinetics, efficacy, and safety of its FACTOR X coagulation product in subjects with hereditary FACTOR X deficiency. The data were presented at the Hemostasis and Thrombosis Re...

Antifungal Therapeutics Market Global Trends and 2019 Forecasts Now Available at MarketReportsOnline.com

DALLAS, April 20, 2015 /PRNewswire/ --   MarketReportsOnline.com adds "Global Antifungal Therapeutics Market" research report to the Pharmaceuticals segment of its online business intelligence and data library.  Antifungal agents are drugs used for the treatment of fungal infections that can infect almost any part of the body including skin, nails, respiratory tract, urogenital tract...

Key element in bacterial immune system discovered

A Univ. of Otago scientist is a member of an international research team that has made an important discovery about the workings of a bacterial immune system. The finding could lead to the development of tailor-made RNA-editing tools. RNA is the mol...

Ferring collaborates on novel IBD drug development

Project in partnership with Paris-based Institut Pasteur

Agenus to Report First Quarter 2015 Financial Results on April 23, 2015; Conference Call to Follow

Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2015 financial results before the market opens on Thursday, April 23, 2015. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day. To access the live call, dial 866-233-4585 (U.S.) or 416-640-5946 (international). The call will also be webcast and will be access...

Monday’s most followed in U.S. including Morgan Stanley, SunTrust, Hasbro, Costco, Michael Kors, Royal Caribbean, P&G, Raytheon, Symantec, Merck, Halliburton

U.S. shares rebounded as China’s central bank cut lenders’ reserve requirements and Morgan Stanley earnings topped forecasts. The S&P 500 (INDEXSP:.INX) gained 1 percent to 2,102 at 11:46 a.m. in New York. The 30-company Dow Jones Ind...

Ligand Partner TG Therapeutics Presents Positive Pre-clinical Data on IRAK4 Compounds at the American Association for Cancer Research (AACR) Annual Meeting

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner TG Therapeutics, Inc. (NASDAQ:TGTX) today announced the first presentation of preclinical data demonstrating single agent and combination activity of two of TG Therapeutics’ IRAK4 inhibitor compounds under development. This pre-clinical data was presented yesterday at the 106th Annual Meeting of ...

PhRMA Member Companies Invested $51.2 Billion in R&D in 2014

WASHINGTON, April 20, 2015 /PRNewswire-USNewswire/ -- Pharmaceutical Research and Manufacturers of America's (PhRMA) member companies invested an estimated $51.2 billion last year in the research and development (R&D) of new innovative treatments and cures. The figure represents the majority of all biopharmaceutical R&D spending – both public and private – in the United States....

Ingenuity Health Research Flags Potentially High Rate of Medication Nonadherence Among Those with Serious Mental Illness

BALTIMORE, April 20, 2015 /PRNewswire/ -- Ameritox's Ingenuity Health, a leading provider of monitoring solutions to behavioral health clinicians, today presented clinical research at the National Council of Behavioral Health annual conference in Orlando, Fla., showing that nearly 25 percent of the samples collected from patients with serious mental illness (SMI) did not contain the prescribe...

Cardiovascular study sets Sanofi on course to refile Lyxumia

Sanofi's diabetes therapy Lyxumia has been given a clean bill of health in a cardiovascular outcomes trial, opening the door for the company to file the drug for approval in the US later this year.The French drugmaker withdrew its marketing applicati...

cCAM Biotherapeutics Announces Initiation of Phase 1 Trial of CM-24, a Novel Immune Checkpoint Inhibitor for Cancer Immunotherapy

cCAM Biotherapeutics, a biopharmaceutical company focused on the discovery and development of novel cancer immunotherapies, announced today that the first patient was dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory monoclonal antibody (mAb) for the treatment

Purdue Pharma Names J. Alan Butcher Senior Vice President of Licensing & Business Development

STAMFORD, Conn., April 20, 2015 /PRNewswire/ -- Purdue Pharma, a leading specialty pharmaceutical company, today announced that Alan Butcher has joined the company as Senior Vice President of Licensing & Business Development. Alan will have responsibility for all of Purdue's efforts to acquire or in-license commercial, near-commercial, and development-stage products that would benefit fro...

Bruker Introduces Next-Generation GigaHertz NMR Technology at ENC 2015

Confluence of Major NMR Methods and Instrumentation Advances Enables Next-Generation GHz Technology with Focus on Structural Biology, Macromolecular Complexes, Membrane Proteins and Intrinsically Disordered Proteins (IDP) At the 56th Experimental Nuclear Magnetic Resonance Conference (www.enc-conference.org), Bruker announced it is launching its next-g...

Bruker Announces Innovative, High-Performance and Cost-Effective NMR Solutions for the Pharmaceutical Industry

Fragment-based Drug Discovery Automated Small-molecule Structure Verification On-the-fly Optimization of Pharma Chemical Processes Pharma QC Raw Materials Screening, and Pharma NMR Lab Connectivity At the 56th Experimental Nuclear Magnetic Resonance Conference (

FDA Approves New Formulation of MINOCIN® (minocycline) for Injection

- Grants Qualified Infectious Disease Product (QIDP) Designation for new potential indications, including hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and certain gram-negative infections in cystic fibrosis patients - Third QIDP Designation for Company’s Infectious Disease Portfolio The Medic...

Pernix Therapeutics Inc. Obtains Six Months U.S. Pediatric Exclusivity for Treximet

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Pediatric Exclusivity has been granted by the U.S Food and Drug Administration (FDA) for studies conducted on Treximet® (sumatriptan/naproxen sodium), effective April 16, 2015

Treatment of Methicillin-Resistant Staphylococcus aureus

Is there a drug that's superior to vancomycin in the treatment of MRSA infections? Seminars in Respiratory and Critical Care Medicine

Transgenomic Launches New Multiplexed ICE-COLD PCR™ Service in Biomarker Identification Business

Multiplexed ICE-COLD PCR a Benchmark for Accuracy and Sensitivity in Mutation Detection across the Entire Development Spectrum through Clinical Trials Visit us at 2015 AACR Annual Meeting, Booth 2149 Transgenomic, Inc. (NASDAQ:TBIO) today announced that its groundbreaking Multiplexed ICE COLD PCR™ (MX-ICP) technology is now available ...

Foundation Medicine Announces Its Collaboration with the National Cancer Institute on Exceptional Responders Initiative

First-of-its-kind Exploratory Study Investigates Unique Molecular Indicators of Tumors Associated with Exceptional Treatment Responses to Drug Therapies in Patients With Cancer Foundation Medicine, Inc. (NASDAQ:FMI) today announced that it has entered into a Collaboration

Restrictive Drug Plan Regulations Will Hurt Patients

DALLAS, April 20, 2015 /PRNewswire-USNewswire/ -- Increasing unnecessary regulations on drug plans could inflict higher costs on the 220 million Americans who get their medications through a managed drug plan, according to a  new report by National Center for Policy Analysis Senior Fellow Devon Herrick. "The degree to which drug benefit plans are managed efficiently helps makes medications...

Study suggests new drug strategy for insulin-influenced tumor growth

Drugs that target insulin pathways to slow or stop the growth of brain tumors are going in the right direction but appear to be on the wrong track, according to new research at Rice University.

AAC Holdings, Inc. Completes Rhode Island Acquisition

Purchase signals AAC’s continued expansion of outpatient strategy; creates strong regional footprint AAC Holdings, Inc. (NYSE: AAC), through its applicable subsidiary, has completed the previously announced acquisition of Clinical Services of Rhode Island, Inc. (“CSRI”), a provider of intensive outpatient substance abuse treatment services, for $...

Merck seeks new Keytruda indication in US

Merck is seeking FDA approval for its successful melanoma drug Keytruda to be used treating lung cancer. The Supplemental Biologics License Application (sBLA) is for the use of Keytruda (pembrolizumab) – an anti-PD1 (programmed death 1) therapy – in advanced non-small cell lung cancer (NSCLC). The drug previously received breakthrough therapy designation for this area in October last year. rea...


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks